ISG20 promotes local tumor immunity and contributes to poor survival in human glioma

Gao, Mengqi; Lin, Yi Hui; Liu, Xing; Li, Yiming; Zhang, Chuanbao; Wang, Zheng; Wang, Zhiliang; Wang, Yulin; Guo, Zongze

doi:10.1080/2162402x.2018.1534038

Cited by 45 publications

(39 citation statements)

References 71 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In human glioma, ISG20 was positively correlated to immune checkpoints (PD-1 and PD-L1) and suppressed the adaptive immune response. In addition, high expression of ISG20 predicted poor overall survival in glioma [52]. Similarly, patients with high expression of ISG20 had shorter overall survival time in our present study.…”

Section: Discussionsupporting

confidence: 81%

ISG20 serves as a potential biomarker and drives tumor progression in clear cell renal cell carcinoma

Ruan

Gao

et al. 2020

Aging

View full text Add to dashboard Cite

Clear cell renal cell carcinoma (ccRCC) is one of the most common malignancies and lacks reliable biomarkers for diagnosis and prognosis, which results in high incidence and mortality rates of ccRCC. In this study, ISG20, HJURP, and FOXM1 were identified as hub genes via weighted gene co-expression network analysis (WGCNA) and Cox regression analysis. Samples validation showed that only ISG20 was up-regulated in ccRCC. Therefore, ISG20 was selected for further study. High ISG20 expression was associated with poor overall survival and disease-free survival. Furthermore, the expression of ISG20 could effectively differentiate ccRCC from normal tissues and was positively correlated to clinical stages. Functional experiments proved that knockdown of ISG20 expression could obviously inhibit cell growth, migration, and invasion in ccRCC cells. To find the potential mechanisms of ISG20, gene set enrichment analysis (GSEA) was performed and revealed that high expression of ISG20 was significantly involved in metastasis and cell cycle pathways. In addition, we found that ISG20 could regulate the expression of MMP9 and CCND1. In conclusion, these findings suggested that ISG20 promoted cell proliferation and metastasis via regulating MMP9/CCND1 expression and might serve as a potential biomarker and therapeutic target in ccRCC.

show abstract

Section: Discussionsupporting

confidence: 81%

ISG20 serves as a potential biomarker and drives tumor progression in clear cell renal cell carcinoma

Ruan

Gao

et al. 2020

Aging

View full text Add to dashboard Cite

show abstract

“…In this study, we screened out genes significant to survival of melanoma patients, majority of them were verified to associated with tumors. ISG20 has interferon-related antiviral effects, while a study found that over-expression of ISG20 promotes metastasis and angiogenesis of liver cancer cells (Gao et al, 2019). DTL is involved with the regulation of cell cycles and playing a role in the regulation of DNA damage, so we suggest hat it regulate cycle of melanocytes so that to regulate its progression.…”

Section: Discussionmentioning

confidence: 85%

Identification of differentially expressed methylated genes in melanoma versus nevi using bioinformatics methods

Zhang

Jiang

et al. 2020

PeerJ

View full text Add to dashboard Cite

Background Melanoma is a highly invasive malignant skin tumor. While melanoma may share some similarities with that of melanocytic nevi, there also exist a number of distinct differences between these conditions. An analysis of these differences may provide a means to more effectively evaluate the etiology and pathogenesis of melanoma. In particular, differences in aberrant methylation expression may prove to represent a critical distinction. Methods Data from gene expression datasets (GSE3189 and GSE46517) and gene methylation datasets (GSE86355 and GSE120878) were downloaded from the GEO database. GEO2R was used to obtain differentially expressed genes (DEGs) and differentially methylation genes (DMGs). Function and pathway enrichment of selected genes were performed using the DAVID database. A protein-protein interaction (PPI) network was constructed by STRING while its visualization was achieved with use of cytoscape. Primary melanoma samples from TCGA were used to identify significant survival genes. Results There was a total of 199 genes in the hypermethylation-low expression group, while 136 genes in the hypomethylation-high expression group were identified. The former were enriched in the biological processes of transcription regulation, RNA metabolism and regulation of cell proliferation. The later were highly involved in cell cycle regulation. 13 genes were screened out after survival analysis and included: ISG20, DTL, TRPV2, PLOD3, KIF3C, DLGAP4, PI4K2A, WIPI1, SHANK2, SLC16A10, GSTA4O, LFML2A and TMEM47. Conclusion These findings reveal some of the methylated differentially expressed genes and pathways that exist between melonoma and melanocytic nevi. Moreover, we have identified some critical genes that may help to improve the diagnosis and treatment of melanoma.

show abstract

“…The ISG20 gene was first introduced by Gongora et al (1997) as a promyelocytic leukemia nuclear body (PML-NB)-associated protein. The expression of ISG20 is reduced in IDH mutant tumors and ISG20 can promote local tumor immunity and may serve as a potential therapeutic target of human glioma (Gao et al, 2019). This is very interesting: all these identified genes are somehow related to interferons and/or immune response.…”

Section: Discussionmentioning

confidence: 99%

Screening and identification of key candidate genes and pathways in myelodysplastic syndrome by bioinformatic analysis

Ying¹

2019

PeerJ

View full text Add to dashboard Cite

Myelodysplastic syndrome (MDS) is a heterogeneous hematologic malignancy derived from hematopoietic stem cells and the molecular mechanism of MDS remains unclear. This study aimed to elucidate potential markers of diagnosis and prognosis of MDS. The gene expression profiles GSE19429 and GSE58831 were obtained and downloaded from the Gene Expression Omnibus (GEO) database. The differentially expressed genes (DEGs) in MDS were screened using GEO2R and overlapped DEGs were obtained with Venn Diagrams. Then, Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway functional enrichment analyses, protein–protein interaction network establishment and survival analyses were performed. Functional enrichment analysis indicated that these DEGs were significantly enriched in the interferon signaling pathway, immune response, hematopoietic cell lineage and the FOXO signaling pathway. Four hub genes and four significant modules including 25 module genes were obtained via Cytoscape MCODE. Survival analysis showed that the overall survival of MDS patients having BLNK, IRF4, IFITM1, IFIT1, ISG20, IFI44L alterations were worse than that without alterations. In conclusion, the identification of these genes and pathways helps understand the underlying molecular mechanisms of MDS and provides candidate targets for the diagnosis and prognosis of MDS.

show abstract

ISG20 promotes local tumor immunity and contributes to poor survival in human glioma

Cited by 45 publications

References 71 publications

ISG20 serves as a potential biomarker and drives tumor progression in clear cell renal cell carcinoma

ISG20 serves as a potential biomarker and drives tumor progression in clear cell renal cell carcinoma

Identification of differentially expressed methylated genes in melanoma versus nevi using bioinformatics methods

Screening and identification of key candidate genes and pathways in myelodysplastic syndrome by bioinformatic analysis

Contact Info

Product

Resources

About